Peptides, without the storytelling.

Do peptides actually do anything to your skin?

Science vs marketing: what 19 clinical trials show — and hide.

A meta-analysis published on 17 March 2026 in Frontiers in Medicine did what few brands dare to: pool 19 randomised controlled trials (1,341 participants, PRISMA protocol, PROSPERO registration) and look coldly at what peptides do to skin. The verdict is more nuanced than any packaging.

What the science confirms

Hydration and brightness are the most robust results. On wrinkles, the effect is real but modest — and above all, it's almost entirely driven by oral formulations: the oral polypeptide subgroup reaches an MD of 1.5 (p=0.01), where topicals struggle. Of the 19 trials, 17 tested oral, only 2 topical. That's the first bias to keep in mind.

The trials that hold up

SURMOUNT-5 settled it. But is that the end of the story?

Semaglutide → Tirzepatide → Retatrutide: the efficacy race.

In 2025, the New England Journal of Medicine published the first direct head-to-head trial of tirzepatide versus semaglutide. The result was unambiguous: tirzepatide wins. But behind the headline figure lies a therapeutic hierarchy that's moving fast.

Mean weight loss, molecule by molecule

SURMOUNT-5: the exact data

751 adults with obesity, no diabetes, 72 weeks, maximum tolerated dose in both arms. Tirzepatide wins clearly, with a safety profile comparable — not superior, comparable — to semaglutide's.

From AMPs to ACPs: an immunotherapy of the future?

Antimicrobial peptides as an anticancer weapon — promising, but still early.

Antimicrobial peptides (AMPs) — our natural defence molecules — interest oncology for an elegant reason: they distinguish cancer cells from healthy ones by the charge of their membrane. But let's be clear on the stage: this is essentially preclinical research, with a handful of early trials.

Why they target the tumour

Cancer-cell membranes overexpose phosphatidylserine (negatively charged) and show a more electronegative surface potential. Cationic (positively charged) AMPs are drawn to them like a magnet, while healthy cells keep their charged phospholipids on the inner leaflet. Hence a natural selectivity. Documented mechanisms: direct membrane lysis, apoptosis induction, immunomodulation (NK-cell recruitment), and targeting of the tumour microenvironment.

The most credible lead: AMP + immunotherapy

The AMP + checkpoint inhibitor (anti-PD-1/PD-L1) combination is the most discussed strategy: AMPs lyse tumour cells and release antigens — an "in situ vaccine" — that potentiates the immune response triggered by the checkpoints. Attractive on paper; still to be demonstrated in the clinic.

7 of the best-selling injectables. Zero pass the test.

We took the peptides influencers push hardest and ran each through the test of human evidence.

Since GLP-1s went mainstream, a parallel market of injectables has exploded — "biohacking," "looksmaxxing," "research use only" vials sold online. The question nobody asks you: how many of these actually have human efficacy evidence? We checked the seven best-sellers, one by one. The result: none combines solid human evidence, established safety, and legality for human use.

The test, product by product

Triple agonists, gut-brain axis, neuro peptides.

Where research is actually heading — and what's still just a promise.

If tirzepatide was the story of 2023 and retatrutide of 2026, the next frontier is already taking shape. Three directions stand out, at very different levels of maturity.

1. Multi-agonists are scaling up

The move from mono- (semaglutide) to dual (tirzepatide) to triple agonist (retatrutide) isn't incremental: each added receptor opens a metabolic lever. Retatrutide, reaching −28 to −30%, approaches surgical results. The open question: how far can you stack targets without multiplying adverse effects?

2. From weekly injection to daily pill

The real usage revolution may be oral. GLP-1 pills (like orforglipron) aim to preserve weight loss without injection — 2026 maintenance data suggest 75–79% preservation vs 38–49% on placebo. A major adherence shift if confirmed and approved.

3. Gut-brain axis and neurological peptides

GLP-1s also act on the brain (satiety, reward), which explains trials underway beyond weight: sleep apnea (already approved for tirzepatide), knee osteoarthritis, fatty liver, and neuro/addiction leads. This is the most speculative field — many hypotheses, few completed Phase 3 trials outside metabolism.

Approved, unapproved, cosmetic: the table that decides.

The series recapped into one decision grid.

After five issues, one question matters: what can you rely on, and what should you be wary of? Here's the synthesis, sorted by level of evidence.

Which peptides are worth it? Our ranking, evidence-first.

We analyse each peptide one by one. A purchase link appears only if the product combines human evidence + legal OTC status + consistency with our conclusions. The result: among the best-selling "wellness" injectables, none passes.

Our full policy: Affiliate & transparency page.

Do cosmetic peptides actually work?

19 RCTs, 1 341 participants, PRISMA 2020: what the data really say.

The cosmetics industry generates billions with peptides. But if you read the studies instead of the packaging, you'd see a more nuanced picture. Here's what 19 published RCTs actually say — and what they don't.

What the science confirms

The March 2026 SRMA meta-analysis remains the most robust reference: hydration improved significantly, brightness increased, wrinkle reduction is real but modest, and elasticity is inconsistent in pooled analysis.

Notable individual trials

Key trials include BCP 5 000 mg/day over 12 weeks, low-MW hydrolysed collagen over 12 weeks, and Pal-KTTKS over 12 weeks. These trials show reproducible effects on dermal density, hydration and wrinkle reduction, with a good tolerability profile.

What marketing doesn't tell you

• Most trials have undeclared conflicts of interest.
• Topical peptides have limited skin bioavailability.
• Oral formulations systematically outperform creams.
• No long-term topical trial yet has complete histopathology.

Bispecific antibodies: BiTE, DART and the new T-cell engager era

14 FDA approvals, a first solid-tumour BiTE in 2024, and an aggressive 2026 pipeline.

Bispecific antibodies do what nature never did: bind two distinct antigens with one molecule, creating an artificial immunological synapse between a cytotoxic T lymphocyte and a tumour cell. Since 2021, the approval pace has accelerated.

Bispecific anatomy

A conventional antibody has two identical arms. A bsAb has two different arms, each recognizing a distinct target. Structural design determines pharmacology: asymmetric IgG, BiTE, DART, TandAb or biparatopic.

14 FDA-approved bispecifics

Key milestones include blinatumomab in 2014, tebentafusp in 2022, mosunetuzumab and teclistamab in 2022, glofitamab and epcoritamab in 2023, talquetamab and elranatamab in 2023, and tarlatamab in May 2024 as the first BiTE for a major solid tumour.

Tarlatamab: first solid-tumour BiTE

Targeting DLL3 overexpressed in 85% of SCLC, tarlatamab received accelerated approval in 2024 after Phase II results: ORR 40%, median response duration 9.7 months, and a manageable toxicity profile.

Haematology bispecifics

Multiple myeloma concentrates three parallel targets: BCMA with teclistamab and elranatamab, GPRC5D with talquetamab, and FcRH5 with cevostamab. Weekly subcutaneous administration revolutionises logistics versus CAR-T.

DART vs BiTE

DARTs share the BiTE principle but differ structurally: crossed domains stabilised by an interchain disulfide, offering better thermal stability and slightly extended half-life. Flotetuzumab is the first DART in clinical testing for acute myeloid leukaemia.

2025–2026 pipeline

The battle is moving to solid tumours: anbenitamab, retlirafusp alfa, BNT327, bispecific ADCs, PD-1×VEGFR2, and trispecifics in Phase I. The goal is to combine immunoengagement and targeted delivery in one molecule.

Advantages vs CAR-T